{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:22:54Z","timestamp":1788024174824,"version":"build-2784847793"},"reference-count":23,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,11,19]]},"abstract":"<jats:p>Alemtuzumab is a highly efficacious therapy used in the treatment of multiple sclerosis (MS), but uncoupling of T and B cell repopulation during immune reconstitution associates with an increasing range of secondary B cell-mediated autoimmune complications. A 34-year-old woman developed Graves\u2019 disease 11 months following an initial course of alemtuzumab treatment for MS. Nine months following the second treatment with alemtuzumab, the patient presented with spontaneous intramuscular and subcutaneous haemorrhage due to development of an inhibitory autoantibody to coagulation factor VIII. Acquired haemophilia A (AHA) is an extremely rare complication in patients treated with alemtuzumab. Treatment with rituximab may induce a rapid remission of AHA; however, the patient\u2019s high John Cunningham virus (JCV) antibody index and alemtuzumab-induced T cell lymphopenia may lead to an increased risk of progressive multifocal leucoencephalopathy, a potential complication which was unacceptable to the patient.<\/jats:p>","DOI":"10.1136\/bcr-2017-223016","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T01:10:33Z","timestamp":1512522633000},"page":"bcr-2017-223016","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis"],"prefix":"10.1136","volume":"2017","author":[{"given":"Georgia","family":"McCaughan","sequence":"first","affiliation":[{"name":"Haematology Department, Westmead Hospital, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Massey","sequence":"additional","affiliation":[{"name":"Neurology Department, St Vincent\u2019s Hospital, Sydney, New South Wales, Australia"},{"name":"UNSW Medical School, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Sutton","sequence":"additional","affiliation":[{"name":"Neurology Department, St Vincent\u2019s Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Curnow","sequence":"additional","affiliation":[{"name":"Haematology Department, Westmead Hospital, Sydney, New South Wales, Australia"},{"name":"Sydney Centres for Thrombosis and Haemostasis, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307721"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.5","unstructured":"Pisa M ML, D\u2019Angelo A , Martinelli V , et al . First reported case of aquired Hemophilia A(AHA) as secondary autoimmune disease following alemtuzumab treatmentin multiple sclerosis, in 3rdCongress of the European Academy of Neurology . Netherlands: European Journal Of Neurology, 2017."},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.6","unstructured":"Giangrande P . Acquired haemophilia in treatment of haemophilia. Canada: World Federation of Haemophilia, 2012."},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-029850"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.01.009"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.9","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200011000-00010"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300826"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-009-9327-3"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.13","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1212\/NXI.0000000000000194","article-title":"Alemtuzumab long-term immunologic effect: treg suppressor function increases up to 24 months","volume":"3","author":"De Mercanti","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313654110"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.15","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000071362.99021.D9"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jamaneurol.2017.1456","article-title":"Neutropenia in patients with multiple sclerosis treated with alemtuzumab","volume":"74","author":"Gait\u00e1n","year":"2017","journal-title":"JAMA Neurol"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.17","unstructured":"Corporation G. LEMTRADA REMS education program for prescribers. 2015 http:\/\/www.lemtradarems.com\/Docs\/Pdf\/LEMTRADA_REMS_Education_Program_for_Prescribers.pdf"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70161-5"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00415-014-7629-8","article-title":"Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder","volume":"262","author":"Kim","year":"2015","journal-title":"J Neurol"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00430-015-0390-5","article-title":"Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics","volume":"204","author":"Verheyen","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/03009742.2015.1135980","article-title":"JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab","volume":"45","author":"Dom\u00ednguez-Mozo","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371138"},{"key":"2025082801180651000_2017.dec04_1.bcr-2017-223016.23","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bjh.14185","article-title":"Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A","volume":"178","author":"McFadyen","year":"2017","journal-title":"Br J Haematol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-223016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:18:16Z","timestamp":1756369096000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-223016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,5]]},"references-count":23,"alternative-id":["10.1136\/bcr-2017-223016"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-223016","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,5]]}}}